Oral Lefamulin vs Moxifloxacin for Early Clinical Response Among Adults With Community-Acquired Bacterial Pneumonia-Reference-Cited by-同舟云学术

Oral Lefamulin vs Moxifloxacin for Early Clinical Response Among Adults With Community-Acquired Bacterial Pneumonia

Published:2019-11-05 Issue:17 Volume:322 Page:1661
ISSN:0098-7484
Container-title:JAMA
language:en
Short-container-title:JAMA

Author:

Alexander Elizabeth¹,Goldberg Lisa¹,Das Anita F.²,Moran Gregory J.³,Sandrock Christian⁴,Gasink Leanne B.¹,Spera Patricia¹,Sweeney Carolyn¹,Paukner Susanne⁵,Wicha Wolfgang W.⁵,Gelone Steven P.¹,Schranz Jennifer¹

Affiliation:

1. Nabriva Therapeutics US Inc, King of Prussia, Pennsylvania

2. Das Consulting, Guerneville, California

3. Olive View-UCLA Medical Center, Los Angeles, California

4. University of California, Davis, School of Medicine, Sacramento

5. Nabriva Therapeutics GmbH, Vienna, Austria

Publisher

American Medical Association (AMA)

Subject

General Medicine

Link

https://jamanetwork.com/journals/jama/articlepdf/2752331/jama_alexander_2019_oi_190111.pdf

Reference27 articles.

1. Cause-specific long-term mortality rates in patients recovered from community-acquired pneumonia as compared with the general Dutch population.;Bruns;Clin Microbiol Infect,2011

2. Community-acquired pneumonia requiring hospitalization among US adults.;Jain;N Engl J Med,2015

3. The burden of community-acquired bacterial pneumonia in the era of antibiotic resistance.;Peyrani;Expert Rev Respir Med,2019

4. AWARE Ceftaroline Surveillance Program (2008-2010): trends in resistance patterns among Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States.;Pfaller;Clin Infect Dis,2012

5. Antibacterial activity of lefamulin against pathogens most commonly causing community-acquired bacterial pneumonia: SENTRY antimicrobial surveillance program (2015-2016).;Paukner;Antimicrob Agents Chemother,2019

Cited by 83 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Guidelines for Antibiotics Prescription in Critically Ill Patients;Indian Journal of Critical Care Medicine;2024-08-10

2. Finding value in novel antibiotics: How can infectious diseases adopt incremental cost-effectiveness to improve new antibiotic utilization?;Diagnostic Microbiology and Infectious Disease;2024-06

3. Pharmacotherapies for multidrug-resistant gram-positive infections: current options and beyond;Expert Opinion on Pharmacotherapy;2024-05-23

4. Identifying the Best Initial Oral Antibiotics for Adults with Community-Acquired Pneumonia: A Network Meta-Analysis;Journal of General Internal Medicine;2024-02-15

5. Safety and Pharmacokinetics Following Oral or Intravenous Lefamulin in Adults With Cystic Fibrosis;Clinical Therapeutics;2024-02